Published in Gut on July 01, 2010
Hepatorenal syndrome. World J Gastroenterol (2012) 0.93
Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II). Wien Klin Wochenschr (2013) 0.93
Hepatic hydrothorax: clinical features, management, and outcomes in 77 patients and review of the literature. Medicine (Baltimore) (2014) 0.90
Selection of a TIPS stent for management of portal hypertension in liver cirrhosis: an evidence-based review. World J Gastroenterol (2014) 0.89
Therapy Algorithm for Portal Vein Thrombosis in Liver Cirrhosis: The Internist's Point of View. Viszeralmedizin (2014) 0.87
Clinical outcome and predictors of survival after TIPS insertion in patients with liver cirrhosis. World J Gastroenterol (2012) 0.86
Transjugular intrahepatic porto-systemic shunt in the elderly: Palliation for complications of portal hypertension. World J Hepatol (2012) 0.85
Long-term follow-up of TIPS created with expanded poly-tetrafluoroethylene covered stents. Dig Dis Sci (2013) 0.85
Role of TIPS in Improving Survival of Patients with Decompensated Liver Disease. Int J Hepatol (2011) 0.83
Parallel shunt for the treatment of transjugular intrahepatic portosystemic shunt dysfunction. Korean J Radiol (2013) 0.83
The management of hospitalized patients with cirrhosis: the Mount Sinai experience and a guide for hospitalists. Dig Dis Sci (2011) 0.82
TIPS improves liver transplantation-free survival in cirrhotic patients with refractory ascites: an updated meta-analysis. World J Gastroenterol (2014) 0.81
Transjugular intrahepatic portosystemic shunt: indications, contraindications, and patient work-up. Semin Intervent Radiol (2014) 0.81
Clinical course and prognostic factors of hepatorenal syndrome: A retrospective single-center cohort study. World J Hepatol (2013) 0.81
Hepatorenal syndrome: outcome of response to therapy and predictors of survival. Gastroenterol Res Pract (2015) 0.78
Transjugular intrahepatic portosystemic shunt vs endoscopic therapy in preventing variceal rebleeding. World J Gastroenterol (2012) 0.77
Efficacy of covered and bare stent in TIPS for cirrhotic portal hypertension: A single-center randomized trial. Sci Rep (2016) 0.77
Transjugular intrahepatic portosystemic shunt in refractory chylothorax due to liver cirrhosis. World J Gastroenterol (2013) 0.77
Prognosis of Acute Kidney Injury and Hepatorenal Syndrome in Patients with Cirrhosis: A Prospective Cohort Study. Int J Nephrol (2015) 0.77
Therapeutic alternatives for the treatment of type 1 hepatorenal syndrome: A Delphi technique-based consensus. World J Hepatol (2016) 0.76
Development of a rat model of D-galactosamine/lipopolysaccharide induced hepatorenal syndrome. World J Gastroenterol (2015) 0.76
How quickly does ascites respond to TIPS? Clinical follow-up of a cohort of eighty patients. Diagn Interv Radiol (2014) 0.75
Symptomatic hepatic hydrothorax successfully treated with transjugular intrahepatic portosystemic shunt (TIPS)-role of titration of portosystemic gradient reduction to avoid post-TIPS encephalopathy. Clin Case Rep (2014) 0.75
Clinical management of advanced schistosomiasis: a case of portal vein thrombosis-induced splenomegaly requiring surgery. BMJ Case Rep (2014) 0.75
Management of hepatorenal syndrome. World J Nephrol (2015) 0.75
Automated low flow pump system for the treatment of refractory ascites: a single-center experience. Langenbecks Arch Surg (2015) 0.75
Changes in Kidney Function After Transjugular Intrahepatic Portosystemic Shunts Versus Large-Volume Paracentesis in Cirrhosis: A Matched Cohort Analysis. Am J Kidney Dis (2016) 0.75
Outcomes of transjugular intrahepatic portosystemic shunts for ascites. Semin Intervent Radiol (2014) 0.75
Compensation by collateral circulation determines invasive therapeutic indications for patients with Budd-Chiari syndrome. Gut (2012) 0.75
Prognostic Significance of Ascites and Serum Sodium in Patients with Low Meld Scores. Med Arch (2016) 0.75
Hepatorenal Syndrome: A Review of Pathophysiology and Current Treatment Options. Semin Intervent Radiol (2015) 0.75
Transjugular intrahepatic portosystemic stent shunt for medically refractory hepatic hydrothorax: A systematic review and cumulative meta-analysis. World J Hepatol (2015) 0.75
Percutaneous Portosystemic Shunts: TIPS and Beyond. Semin Intervent Radiol (2014) 0.75
Hepatorenal syndrome: Update on diagnosis and therapy. World J Hepatol (2017) 0.75
Renal dysfunction in cirrhosis: acute kidney injury and the hepatorenal syndrome. Gastroenterol Rep (Oxf) (2017) 0.75
Diastolic dysfunction in cirrhosis. Heart Fail Rev (2016) 0.75
Role of Kupffer cells in host defense and liver disease. Liver Int (2006) 2.55
Suramin inhibits death receptor-induced apoptosis in vitro and fulminant apoptotic liver damage in mice. Nat Med (2004) 1.54
Atrial natriuretic peptide preconditioning protects against hepatic preservation injury by attenuating necrotic and apoptotic cell death. J Hepatol (2003) 1.45
Hepatic arterial buffer response in patients with advanced cirrhosis. Hepatology (2002) 1.21
Inhibition of c-Jun-N-terminal-kinase sensitizes tumor cells to CD95-induced apoptosis and induces G2/M cell cycle arrest. Cancer Res (2005) 1.11
Glutathione protects the rat liver against reperfusion injury after prolonged warm ischemia. Ann Surg (2004) 1.08
The impact of acute kidney injury in cirrhosis: does definition matter? Gut (2013) 1.07
Induction of cellular resistance against Kupffer cell-derived oxidant stress: a novel concept of hepatoprotection by ischemic preconditioning. Hepatology (2003) 1.00
Intravenous administration of glutathione protects parenchymal and non-parenchymal liver cells against reperfusion injury following rat liver transplantation. World J Gastroenterol (2004) 1.00
Kupffer cell activation in normal and fibrotic livers increases portal pressure via thromboxane A(2). J Hepatol (2007) 0.95
Characterization of organic anion transporter regulation, glutathione metabolism and bile formation in the obese Zucker rat. J Hepatol (2005) 0.95
Rapid development of esophageal squamous cell carcinoma after liver transplantation for alcohol-induced cirrhosis. Transpl Int (2003) 0.94
Expression, cellular distribution, and prognostic relevance of TRAIL receptors in hepatocellular carcinoma. Clin Cancer Res (2010) 0.93
Amiloride reduces portal hypertension in rat liver cirrhosis. Gut (2010) 0.92
Protein kinase A dependent signalling mediates anti-apoptotic effects of the atrial natriuretic peptide in ischemic livers. J Hepatol (2004) 0.92
The atrial natriuretic peptide and cGMP: novel activators of the heat shock response in rat livers. Hepatology (2002) 0.89
Treatment of Crigler-Najjar type 1 disease: relevance of early liver transplantation. J Pediatr Surg (2003) 0.89
Psychiatric and psychosocial outcome of orthotopic liver transplantation. Psychother Psychosom (2002) 0.88
P60-c-src suppresses apoptosis through inhibition of caspase 8 activation in hepatoma cells, but not in primary hepatocytes. J Hepatol (2006) 0.87
Intraperitoneal LPS amplifies portal hypertension in rat liver fibrosis. Lab Invest (2010) 0.87
Use of a mixed endothelin receptor antagonist in portopulmonary hypertension: a safe and effective therapy? Gastroenterology (2005) 0.87
Portal pressure regulation following Kupffer cell activation: control of prostaglandin production by heme oxygenases. Digestion (2013) 0.85
Benefit of TIPS for patients with refractory or recidivant ascites: serum bilirubin may make the difference. Hepatology (2005) 0.85
Hepatocyte cytoskeleton during ischemia and reperfusion--influence of ANP-mediated p38 MAPK activation. World J Gastroenterol (2005) 0.83
Terlipressin for hepatorenal syndrome: continuous infusion as an alternative to i.v. bolus administration. Gastroenterology (2009) 0.83
The atrial natriuretic peptide as a regulator of Kupffer cell functions. Shock (2002) 0.82
Ischaemic and pharmacological preconditionings protect liver via adenosine and redox status following hepatic ischaemia/reperfusion in rats. Clin Sci (Lond) (2008) 0.82
Kupffer-cell specific induction of heme oxygenase 1 (hsp32) by the atrial natriuretic peptide--role of cGMP. J Hepatol (2003) 0.82
Stimulation of p38 MAPK by hormonal preconditioning with atrial natriuretic peptide. World J Gastroenterol (2002) 0.82
Microsatellite instability, KRAS mutations and cellular distribution of TRAIL-receptors in early stage colorectal cancer. PLoS One (2012) 0.82
Glutathione treatment protects the rat liver against injury after warm ischemia and Kupffer cell activation. Digestion (2002) 0.81
Improved quality of life in patients with refractory or recidivant ascites after insertion of transjugular intrahepatic portosystemic shunts. Digestion (2002) 0.80
Infection as a Trigger for Portal Hypertension. Dig Dis (2015) 0.80
Treatment with the leukotriene inhibitor montelukast for 10 days attenuates portal hypertension in rat liver cirrhosis. Hepatology (2010) 0.79
ANP-induced decrease of iron regulatory protein activity is independent of HO-1 induction. Am J Physiol Gastrointest Liver Physiol (2004) 0.78
Functional relevance of the cannabinoid receptor 2 - heme oxygenase pathway: a novel target for the attenuation of portal hypertension. Life Sci (2013) 0.78
Insufficient sensitivity of reagent strips for spontaneous bacterial peritonitis. Hepatology (2007) 0.77
Drug-Induced Liver Injury and Individual Cell Models. Dig Dis (2015) 0.77
Kupffer cell activation by hydrogen peroxide: a new mechanism of portal pressure increase. Shock (2010) 0.77
Liver dysfunction in patients with IBD under immunosuppressive treatment: do we need to fear? Gut (2010) 0.76
PI 3-kinase pathway is responsible for antiapoptotic effects of atrial natriuretic peptide in rat liver transplantation. World J Gastroenterol (2006) 0.76
Antioxidant effects of xanthohumol and functional impact on hepatic ischemia-reperfusion injury. J Nat Prod (2009) 0.76
High age and low sodium urine concentration are associated with poor survival in patients with hepatorenal syndrome. Ann Hepatol (2013) 0.76
Human monocyte-derived cells with individual hepatocyte characteristics: a novel tool for personalized in vitro studies. Lab Invest (2012) 0.75
Renal failure in cirrhosis. N Engl J Med (2010) 0.75
Reliable Quantification of the Potential for Equations Based on Spot Urine Samples to Estimate Population Salt Intake: Protocol for a Systematic Review and Meta-Analysis. JMIR Res Protoc (2016) 0.75
Progress in treatment of massive ascites and hepatorenal syndrome. World J Gastroenterol (2006) 0.75
Role of cholesterol determination in ascitic fluid analysis. Hepatology (2009) 0.75
Short-term treatment with mycophenolic acid increases bile flow in continuously perfused and cold-preserved rat livers and does not affect hepatic ischemia-reperfusion injury. Transpl Int (2002) 0.75
[The history and status of transplantation medicine]. Pharm Unserer Zeit (2005) 0.75
Role of cysteinyl-leukotrienes for portal pressure regulation and liver damage in cholestatic rat livers. Lab Invest (2013) 0.75
The Challenge of Drug-Induced Liver Injury (DILI) / Challenges and Management of Liver Cirrhosis. Preface. Dig Dis (2015) 0.75
In-vivo quantification of hepatic 11beta-hydroxysteroid dehydrogenase type I activity--a preliminary study. Clin Biochem (2002) 0.75
Daily profile of circulating C-type natriuretic peptide in pre-ascitic cirrhosis and in normal subjects: relationship with renal function. Scand J Gastroenterol (2007) 0.75